Biohaven Announces Proposed Public Offering of Common Shares

NEW HAVEN, Conn., Dec. 10, 2018 – — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of 3,000,000 of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven.  In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 common shares at the public offering price, less underwriting discounts and commissions.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. 

Goldman Sachs & Co. LLC and Piper Jaffray & Co. are acting as joint book-running managers of the offering.

The offering is being made only by means of a prospectus.  When available, copies of the prospectus related to the offering may be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.


Dr. Vlad Coric

Chief Executive Officer

Biohaven Pharmaceutical Holding Company Ltd.

Phone: (203) 404-0410


SOURCE Biohaven Pharmaceutical Holding Company Ltd.

Related Links

Leave a Reply

Your email address will not be published. Required fields are marked *